Advances in nanoprobes for molecular MRI of Alzheimer's disease
- 1 March 2024
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1946
Abstract
Alzheimer's disease is the most common cause of dementia and a leading cause of mortality in the elderly population. Diagnosis of Alzheimer's disease has traditionally relied on evaluation of clinical symptoms for cognitive impairment with a definitive diagnosis requiring post‐mortem demonstration of neuropathology. However, advances in disease pathogenesis have revealed that patients exhibit Alzheimer's disease pathology several decades before the manifestation of clinical symptoms. Magnetic resonance imaging (MRI) plays an important role in the management of patients with Alzheimer's disease. The clinical availability of molecular MRI (mMRI) contrast agents can revolutionize the diagnosis of Alzheimer's disease. In this article, we review advances in nanoparticle contrast agents, also referred to as nanoprobes, for mMRI of Alzheimer's disease.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological DiseaseKeywords
Funding Information
- Fondation Leducq (22CVD03)
- National Institutes of Health (R01CA159042, R01HD094347, R01HL159988, R33HD105593, R61HD105593, RF1AG070149, U01DE028233)
- American Heart Association (19CSLOI34660145)
- Gillson Longenbaugh Foundation
This publication has 165 references indexed in Scilit:
- Blood‐brain barrier permeability is increased in early Alzheimer’s disease and correlates with brain microstructureAlzheimer's & Dementia, 2022
- Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer diseaseAnnals of Clinical and Translational Neurology, 2022
- Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer DiseaseJAMA Neurology, 2021
- Blood–brain barrier permeability measured by contrast‐enhanced MRI in early Alzheimer’s diseaseAlzheimer's & Dementia, 2020
- Amyloid‐β Oligomer‐Targeted Gadolinium‐Based NIR/MR Dual‐Modal Theranostic Nanoprobe for Alzheimer's DiseaseAdvanced Functional Materials, 2020
- Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without DementiaJAMA, 2019
- Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal PersonsJAMA, 2017
- In Vivo Micro-CT Imaging of Human Mesenchymal Stem Cells Labeled with Gold-Poly-l-Lysine NanocomplexesAdvanced Functional Materials, 2016
- Amyloid-β and TauJAMA Neurology, 2014